Verrica pharmaceuticals inc. (VRCA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating expenses:
Research and development

4,892

3,972

3,049

3,928

4,487

4,917

3,467

3,515

927

1,118

1,120

977

515

General and administrative

4,988

4,018

3,494

3,593

3,539

3,271

2,865

1,955

961

316

238

118

55

Total operating expenses

9,880

7,990

6,543

7,521

8,026

8,188

6,332

5,470

1,888

1,434

1,358

1,095

570

Loss from operations

-9,880

-7,990

-6,543

-7,521

-8,026

-8,188

-6,332

-5,470

-1,888

-1,434

-1,358

-1,095

-570

Other income (expense):
Interest income

278

354

453

523

547

610

427

153

41

-

-

-

-

Interest expense

220

-

-

-

-

-

-

-

-

-

-

-

-

Other expense

-

-

-

3

-

-

1

-

-

-

-

-

-

Interest expense - related party

-

-

-

-

-

-

-

-

-

-

1

-

-

Total other income

58

353

453

520

547

610

426

153

41

-1

-1

-

-

Net loss

-9,822

-7,637

-6,090

-7,001

-7,479

-7,578

-5,906

-5,317

-1,847

-1,435

-1,359

-1,095

-570

Net loss per share, basic and diluted

-0.39

-0.31

-0.24

-0.28

-0.30

-0.30

-0.24

-0.92

-0.65

-0.50

-0.48

-0.38

-0.20

Weighted average common shares outstanding, basic and diluted

24,964

24,922

24,893

24,875

24,857

24,847

24,847

5,751

2,850

2,850

2,850

2,850

2,849

Net loss

-9,822

-7,637

-6,090

-7,001

-7,479

-7,578

-5,906

-5,317

-1,847

-1,435

-1,359

-1,095

-570

Other comprehensive gain:
Unrealized gain on marketable securities

-

-7

-11

27

28

-

-7

-

-

-

-

-

-

Comprehensive loss

-9,822

-7,644

-6,101

-6,974

-7,451

-7,588

-5,913

-5,317

-1,847

-

-1,359

-

-